Logo image of NRX.CA

NUREXONE BIOLOGIC INC (NRX.CA) Stock Price, Quote, News and Overview

TSX-V:NRX - TSX Venture Exchange - CA67059R1091 - Common Stock - Currency: CAD

0.73  -0.01 (-1.35%)

NRX.CA Quote, Performance and Key Statistics

NUREXONE BIOLOGIC INC

TSX-V:NRX (7/23/2025, 7:00:00 PM)

0.73

-0.01 (-1.35%)

Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
Statistics
52 Week High0.83
52 Week Low0.52
Market Cap58.41M
Shares80.01M
Float75.41M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO05-08 2012-05-08


NRX.CA short term performance overview.The bars show the price performance of NRX.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15

NRX.CA long term performance overview.The bars show the price performance of NRX.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of NRX.CA is 0.73 CAD. In the past month the price increased by 5.8%. In the past year, price increased by 15.87%.

NUREXONE BIOLOGIC INC / NRX Daily stock chart

About NRX.CA

Company Profile

NRX logo image NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Company Info

NUREXONE BIOLOGIC INC

Minus 1 Entry, Ground Floor Of Bldg B

Haifa ALBERTA IL

Employees: 12

NRX Company Website

NRX Investor Relations

Phone: 972524803034

NUREXONE BIOLOGIC INC / NRX.CA FAQ

What is the stock price of NUREXONE BIOLOGIC INC today?

The current stock price of NRX.CA is 0.73 CAD. The price decreased by -1.35% in the last trading session.


What is the ticker symbol for NUREXONE BIOLOGIC INC stock?

The exchange symbol of NUREXONE BIOLOGIC INC is NRX and it is listed on the TSX Venture Exchange exchange.


On which exchange is NRX.CA stock listed?

NRX.CA stock is listed on the TSX Venture Exchange exchange.


What is the price forecast or stock price prediction for NUREXONE BIOLOGIC INC stock?

9 analysts have analysed NRX.CA and the average price target is 3.12 CAD. This implies a price increase of 326.86% is expected in the next year compared to the current price of 0.73. Check the NUREXONE BIOLOGIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NUREXONE BIOLOGIC INC worth?

NUREXONE BIOLOGIC INC (NRX.CA) has a market capitalization of 58.41M CAD. This makes NRX.CA a Micro Cap stock.


How many employees does NUREXONE BIOLOGIC INC have?

NUREXONE BIOLOGIC INC (NRX.CA) currently has 12 employees.


What are the support and resistance levels for NUREXONE BIOLOGIC INC (NRX.CA) stock?

NUREXONE BIOLOGIC INC (NRX.CA) has a support level at 0.71 and a resistance level at 0.75. Check the full technical report for a detailed analysis of NRX.CA support and resistance levels.


Should I buy NUREXONE BIOLOGIC INC (NRX.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NUREXONE BIOLOGIC INC (NRX.CA) stock pay dividends?

NRX.CA does not pay a dividend.


What is the Price/Earnings (PE) ratio of NUREXONE BIOLOGIC INC (NRX.CA)?

NUREXONE BIOLOGIC INC (NRX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).


NRX.CA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to NRX.CA. When comparing the yearly performance of all stocks, NRX.CA turns out to be only a medium performer in the overall market: it outperformed 56.11% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NRX.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to NRX.CA. While NRX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NRX.CA Financial Highlights

Over the last trailing twelve months NRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -4% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -270.98%
ROE -440.65%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%-15%
Sales Q2Q%N/A
EPS 1Y (TTM)-4%
Revenue 1Y (TTM)N/A

NRX.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to NRX.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst OwnersN/A
Ins Owners5.89%
Short Float %N/A
Short RatioN/A
Analysts
Analysts84.44
Price Target3.12 (327.4%)
EPS Next Y12.5%
Revenue Next YearN/A